NDC 83301-0003-01 - Gabapentin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 83301-0003
- Requested NDC
- 83301-0003-01
- Package NDCs from labels
- 83301-0003-1, 83301-0003-2, 83301-0003-3, 83301-0003-01
- Manufacturer
- Mullan Pharmaceutical Inc. | CSPC Ouyi Pharmaceutical Co., Ltd
- Effective date
- 2025-08-21
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Gabapentin - Mullan Pharmaceutical Inc. | CSPC Ouyi Pharmaceutical Co., Ltd | Mullan Pharmaceutical Inc. | CSPC Ouyi Pharmaceutical Co., Ltd | 2025-08-21 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 83301-0003-1 | Gabapentin | 100 in 1 BOTTLE, PLASTIC | CAPSULE | 100 | 10 | |
| 83301-0003-2 | Gabapentin | 500 in 1 BOTTLE, PLASTIC | CAPSULE | 500 | 10 | |
| 83301-0003-3 | Gabapentin | 1000 in 1 BOTTLE, PLASTIC | CAPSULE | 1000 | 10 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 83301-0003 | GABAPENTIN CAPSULE [MULLAN PHARMACEUTICAL INC.] | 9 | Current NDC, 3 package rows | 20250411_74474aa4-4859-42d2-92d8-f23f18b34e04.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 83301-0003-1 | EA - Each | 83301-0003 | 48fb29f0-710e-4631-a0ae-f2d137c5ce80 | 1 | 2025-07-08 |
| 83301-0003-2 | EA - Each | 83301-0003 | 36eeae7f-ed52-4f55-a41b-deb411872750 | 1 | 2025-07-08 |
| 83301-0003-3 | EA - Each | 83301-0003 | 5fdaad8f-bb94-40a7-a1e6-0ca5cb6b74da | 1 | 2024-10-04 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| GABAPENTIN | GABAPENTIN | Proficient Rx LP | 92c4d589-533b-4fe4-833f-dd68cc1f7e66 | 2019-11-01 | Warnings, Adverse reactions | 310432 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Proficient Rx LP | 2ef99c3d-866a-438b-a340-8beba8d4c457 | 2019-11-01 | Warnings, Adverse reactions | 310431 6CW7F3G59X |
| No7 Perfect and Perfect Intense Advanced All in One Foundation SPF 50 Cool Vanilla | OCTINOXATE, TITANIUM DIOIXIDE, OCTISALATE | BCM Cosmetique SAS | d701c221-9f68-47ff-b766-2f4f1998649f | 2019-10-08 | Warnings | 15FIX9V2JP |
| No7 Perfect and Perfect Intense Advanced All in One Foundation SPF 50 Amber | OCTINOXATE, TITANIUM DIOIXIDE, OCTISALATE | BCM Cosmetique SAS | 7f5e6872-4d26-410e-8afe-16a016f9a399 | 2019-10-08 | Warnings | 15FIX9V2JP |
| No7 Perfect and Perfect Advanced All in One Foundation SPF 50 Warm Ivory | OCTINOXATE, TITANIUM DIOIXIDE, OCTISALATE | BCM Cosmetique SAS | 1124ba7d-a328-409b-8c88-e74bb3e501f5 | 2019-10-08 | Warnings | 15FIX9V2JP |
| No7 Perfect and Perfect Advanced All in One Foundation SPF 50 Honey | OCTINOXATE, TITANIUM DIOIXIDE, OCTISALATE | BCM Cosmetique SAS | 9c407dc7-fcde-4660-9a06-57bd8a6b867d | 2019-10-08 | Warnings | 15FIX9V2JP |
| No7 Perfect and Perfect Intense Advanced All in One Foundation SPF 50 Chestnut | OCTINOXATE, TITANIUM DIOIXIDE, OCTISALATE | BCM Cosmetique SAS | f07e8bb2-30ae-4337-ad60-84f55f2ff354 | 2019-10-08 | Warnings | 15FIX9V2JP |
| Gabapentin | GABAPENTIN | Proficient Rx LP | c78f528f-9192-4037-bfb9-ff5718ed26c5 | 2019-10-01 | Warnings, Adverse reactions | 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Epic Pharma, LLC | 030e656a-e384-49ac-830f-32140c18112d | 2019-01-07 | Warnings, Adverse reactions | 310430 310432 310431 6CW7F3G59X |
| CLE CCC Golden Medium Deep | TITANIUM DIOXIDE, OCTINOXATE, OCTISALATE | KW ABSC, INC. | b7a4847f-b84d-4f36-8787-104eccd838a0 | 2018-12-03 | Warnings | 15FIX9V2JP |
| CLE CCC Warm Medium Deep | TITANIUM DIOXIDE, OCTINOXATE, OCTISALATE | KW ABSC, INC. | 229c20a3-6288-4ac3-9098-6d1622e906ab | 2018-11-29 | Warnings | 15FIX9V2JP |
| CLE CCC Warm Medium Light | TITANIUM DIOXIDE, OCTINOXATE, OCTISALATE | KW ABSC, INC. | fc90fb8a-44b3-47cd-882e-94ed324ed389 | 2018-11-27 | Warnings | 15FIX9V2JP |
| CLE CCC Warm Medium | TITANIUM DIOXIDE, OCTINOXATE, OCTISALATE | KW ABSC, INC. | b585f216-4234-47c5-9a6b-8b133ef48aae | 2018-11-27 | Warnings | 15FIX9V2JP |
| CLE CCC Warm Light | TITANIUM DIOXIDE, OCTINOXATE, OCTISALATE | KW ABSC, INC. | 14891e26-b3b6-4545-99b1-da914b7f5629 | 2018-11-24 | Warnings | 15FIX9V2JP |
| GABAPENTIN | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | a900bafb-8f49-4a01-ba7f-4fb228ec0253 | 2018-11-12 | Warnings, Adverse reactions | 310431 6CW7F3G59X |
| GABAPENTIN | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | 6702ed8f-4aaf-46fa-bf39-db75154aa44c | 2018-10-19 | Warnings, Adverse reactions | 310432 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | 1b73e9db-eddb-49ba-9778-01d39ece4d16 | 2018-09-21 | Warnings, Adverse reactions | 310431 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | f455b415-12a2-4916-b826-246976a8af44 | 2018-09-12 | Warnings, Adverse reactions | 310431 6CW7F3G59X |
| Gabapentin | GABAPENTIN | Aphena Pharma Solutions - Tennessee, LLC | 5fbd601f-df95-4a79-a7d3-c3505e23b913 | 2018-09-06 | Warnings, Adverse reactions | 310430 6CW7F3G59X |
| Additox | TRIFOLIUM PRATENSE, XANTHOXYLUM FRAXINEUM, PHYTOLACCA DECANDRA, ARSENICUM ALBUM, BELLADONNA, CHELIDONIUM MAJUS, LYCOPODIUM CLAVATUM, PHOSPHORICUM ACIDUM, ASPARTAME, BENZALKONIUM CHLORIDE, FORMALINUM, METHYLENE CHLORIDE, METHYLPARABEN, PROPYLPARABEN, SODIUM BENZOATE, SODIUM CITRATE, TITANIUM DIOXIDE, ZINCUM OXYDATUM | BioActive Nutritional, Inc. | 319ee2fe-58e3-495e-bf0d-df201f6fbb1c | 2018-07-18 | Warnings | 15FIX9V2JP |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.